Atrium Therapeutics, Inc. (RNA)

Every figure this model derived for RNA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,134,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 263,900,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 275,051,000 AssetsCurrent 2026-06-30
current liabilities 31,508,000 LiabilitiesCurrent 2026-06-30
equity 214,576,000 StockholdersEquity 2026-06-30
ocf -35,069,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 22,639,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 13,106,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RNA on one particular measure came for.

RatioValue
cash operating margin-116.16
current ratio12.24
current ratio reported8.73
fcf margin-164.33
operating margin-176.24
owner earnings margin-222.22
revenue growth317.69
revenue growth per share317.69
rule of 40141.46
sbc pct revenue57.89

What to be careful about

What this model itself distrusts about RNA's figures. Written by the derivation as it ran, not added afterwards.